Clark & Stuart Inc Has $3.12 Million Position in Abbott Laboratories $ABT

Key Points

• Clark & Stuart Inc. more than doubled its Abbott Laboratories stake in the second quarter, increasing holdings by 126.9% to 34,432 shares valued at approximately $3.12 million. Institutional investors collectively own 75.18% of Abbott’s stock.
• Abbott exceeded quarterly earnings and revenue expectations, reporting $1.31 in adjusted EPS and $12.59 billion in revenue, up 13% year over year. The company issued third-quarter EPS guidance of $1.38–$1.46 and full-year guidance of $5.45–$5.60.
• Wall Street sentiment remains favorable, with Abbott receiving a consensus “Moderate Buy” rating and an average price target of $118.67; the company also declared a $0.63 quarterly dividend, equal to a 2.3% annualized yield.

Clark & Stuart Inc increased its stake in shares of Abbott Laboratories (NYSE:ABT - Free Report) by 126.9% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 34,432 shares of the healthcare product maker's stock after purchasing an additional 19,255 shares during the quarter. Abbott Laboratories makes up about 2.0% of Clark & Stuart Inc's portfolio, making the stock its 17th largest holding. Clark & Stuart Inc's holdings in Abbott Laboratories were worth $3,124,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently added to or reduced their stakes in the stock. Brighton Jones LLC increased its stake in shares of Abbott Laboratories by 10.1% in the fourth quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker's stock valued at $5,850,000 after buying an additional 4,755 shares during the period. Sivia Capital Partners LLC boosted its position in Abbott Laboratories by 3.5% during the 2nd quarter. Sivia Capital Partners LLC now owns 4,768 shares of the healthcare product maker's stock worth $648,000 after buying an additional 162 shares during the period. United Bank grew its holdings in Abbott Laboratories by 7.4% during the 2nd quarter. United Bank now owns 29,004 shares of the healthcare product maker's stock worth $3,945,000 after acquiring an additional 2,001 shares during the last quarter. Main Street Financial Solutions LLC increased its position in Abbott Laboratories by 13.6% in the 2nd quarter. Main Street Financial Solutions LLC now owns 11,894 shares of the healthcare product maker's stock valued at $1,618,000 after acquiring an additional 1,428 shares during the period. Finally, Canada Pension Plan Investment Board raised its stake in shares of Abbott Laboratories by 25.6% during the second quarter. Canada Pension Plan Investment Board now owns 1,435,683 shares of the healthcare product maker's stock valued at $195,267,000 after acquiring an additional 292,547 shares during the last quarter. Institutional investors and hedge funds own 75.18% of the company's stock.

Abbott Laboratories Stock Up 0.4%

Shares of NYSE ABT opened at $111.37 on Friday. The firm has a market cap of $192.71 billion, a PE ratio of 36.04, a P/E/G ratio of 2.15 and a beta of 0.59. Abbott Laboratories has a 12-month low of $81.97 and a 12-month high of $137.49. The company's fifty day simple moving average is $97.27 and its 200 day simple moving average is $99.75. The company has a quick ratio of 0.97, a current ratio of 1.38 and a debt-to-equity ratio of 0.57.

Abbott Laboratories (NYSE:ABT - Get Free Report) last posted its quarterly earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share for the quarter, beating the consensus estimate of $1.28 by $0.03. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. The firm had revenue of $12.59 billion during the quarter, compared to the consensus estimate of $12.52 billion. During the same period in the previous year, the firm posted $1.26 earnings per share. The business's revenue was up 13.0% compared to the same quarter last year. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. As a group, sell-side analysts forecast that Abbott Laboratories will post 5.52 earnings per share for the current fiscal year.

Abbott Laboratories Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, August 17th. Investors of record on Wednesday, July 15th will be given a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a yield of 2.3%. The ex-dividend date of this dividend is Wednesday, July 15th. Abbott Laboratories's payout ratio is presently 81.55%.

Abbott Laboratories News Roundup

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Wolfe Research upgraded Abbott Laboratories (ABT) from “peer perform” to “outperform” and set a $130 target, implying substantial upside from recent trading levels. Benzinga analyst upgrade report
• Positive Sentiment: Abbott’s Established Pharmaceutical Products division is benefiting from emerging-market growth, broad branded-generic offerings and resilient healthcare demand. Expanding biosimilar opportunities could provide an additional long-term growth avenue. Zacks EPD growth report
• Positive Sentiment: Abbott and Google Health announced a multiyear partnership to integrate Abbott’s Lingo continuous glucose-monitoring data into Google’s AI-powered consumer health tools. The collaboration could increase Lingo’s visibility, support personalized metabolic-health services and generate valuable real-world data. Abbott and Google Health Lingo partnership
• Positive Sentiment: Bank of America Securities issued a “buy” recommendation for ABT, reinforcing the constructive Wall Street view. Bank of America buy rating
• Neutral Sentiment: Abbott’s stock outperformed competitors during a strong broader trading session, reflecting market momentum but not a new company-specific fundamental catalyst. MarketWatch trading report
• Neutral Sentiment: Abbott’s PULSE study is evaluating earlier treatment for atrial fibrillation. Positive clinical results could expand future device demand, but the study remains ongoing and carries execution and clinical risk. TipRanks PULSE study report
• Neutral Sentiment: Abbott renewed its blood-donation campaign with the Big Ten amid a U.S. blood shortage. The initiative supports Abbott’s brand and blood-management business, though its direct near-term financial impact is likely limited. Abbott and Big Ten blood donation campaign

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on the company. Weiss Ratings raised Abbott Laboratories from a "sell (d+)" rating to a "hold (c-)" rating in a research report on Thursday, August 6th. Argus reduced their price target on Abbott Laboratories from $140.00 to $125.00 and set a "buy" rating on the stock in a research report on Tuesday, April 21st. Raymond James Financial decreased their price target on Abbott Laboratories from $130.00 to $115.00 and set an "outperform" rating for the company in a research note on Friday, April 17th. The Goldman Sachs Group cut their price objective on Abbott Laboratories from $121.00 to $113.00 and set a "buy" rating on the stock in a research note on Wednesday, May 27th. Finally, Barclays reduced their target price on Abbott Laboratories from $144.00 to $143.00 and set an "overweight" rating on the stock in a report on Monday, April 20th. Three investment analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat, Abbott Laboratories presently has an average rating of "Moderate Buy" and a consensus price target of $118.67.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source